Press release
Psoriatic Arthritis Clinical Trial Pipeline Expands as 20+ Pharma Companies Progress 25+ Novel Therapies Toward Market Entry, Finds DelveInsight | Bristol Myers Squibb, Hansoh BioMedical R&D Company and others
Psoriatic Arthritis Pipeline Report
Explore the latest breakthroughs in the Psoriatic Arthritis treatment landscape. Learn more about the evolving Psoriatic Arthritis pipeline today @ https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Psoriatic Arthritis Pipeline Report
• On 9th March 2026, the FDA approved pharma major Bristol Myers Squibb's (NYSE; BMY) Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). Sotyktu, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first TYK2 inhibitor to be approved for PsA.
• In September 2025, the FDA approved guselkumab (Tremfya) for pediatric PsA - first IL-23 inhibitor approved for children aged ≥6 years (≥40 kg) with active psoriatic arthritis, supported by the Phase 3 PROTOSTAR trial.
• In July 2025, Janssen initiated a Phase 3 study evaluating icotrokinra vs. placebo in active PsA, assessing reduction in signs and symptoms.
• DelveInsight's Psoriatic Arthritis Pipeline Insight report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Psoriatic Arthritis treatment.
• The leading Psoriatic Arthritis companies include Bristol Myers Squibb, Hansoh BioMedical R&D Company, selection and others.
• Promising Psoriatic Arthritis therapies include Sotyktu (deucravacitinib), HS-10374, si-544 and others.
Download for updates and the latest revolution in Psoriatic Arthritis treatment @ https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The Psoriatic Arthritis Pipeline Report Provides
• Detailed insights about companies developing therapies for Psoriatic Arthritis, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Psoriatic Arthritis treatment.
• Psoriatic Arthritis companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Psoriatic Arthritis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Psoriatic Arthritis market.
Learn more about Psoriatic Arthritis Drugs opportunities in our comprehensive Psoriatic Arthritis pipeline report @
https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Psoriatic Arthritis Companies
There are 20+ key companies, such as Bristol Myers Squibb, Hansoh BioMedical R&D Company, selection and others, developing therapies for Psoriatic Arthritis, with Bristol Myers Squibb having its Psoriatic Arthritis drug candidate in the most advanced Phase III stage.
DelveInsight's Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical
Psoriatic Arthritis products have been categorized under various Molecule types such as:
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Discover the latest advancements in Psoriatic Arthritis treatment by visiting our website. Stay informed @
https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Scope of the Psoriatic Arthritis Pipeline Report
• Coverage: Global
• Psoriatic Arthritis companies: Bristol Myers Squibb, Hansoh BioMedical R&D Company, selection and others
• Psoriatic Arthritis Therapies: Sotyktu (deucravacitinib), HS-10374, si-544 and others.
• Psoriatic Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Psoriatic Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriatic Arthritis Clinical Trial Pipeline Expands as 20+ Pharma Companies Progress 25+ Novel Therapies Toward Market Entry, Finds DelveInsight | Bristol Myers Squibb, Hansoh BioMedical R&D Company and others here
News-ID: 4417687 • Views: …
More Releases from DelveInsight
Ovarian Cancer Pipeline Expands with 180+ Companies and 200+ Emerging Therapies, …
DelveInsight's "Ovarian Cancer - Pipeline Insight, 2026" report provides comprehensive insights about 180+ companies and more than 200 pipeline drugs in the Ovarian Cancer pipeline landscape. It covers the Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type. The report highlights inactive pipeline products and explores the commercial and clinical assessment of products from…
Pain Management Devices Market Poised to Reach USD 32.19 Billion by 2034 with a …
The global pain management devices market is witnessing significant transformation, propelled by the rising prevalence of chronic pain conditions, a strategic shift away from opioid-based therapies, and rapid technological integration such as AI-driven neuromodulation and wearable solutions.
Key Takeaways
• February 2026: CURAPOD raised USD 2.2 million in a pre-series A funding round to scale its wearable pain management technology.
• May 2025: Matri launched Matri Pro, a wearable device designed to provide…
Contraceptive Devices Market Projected to Reach USD 32.8 Billion by 2032, Driven …
The global contraceptive devices market is poised for robust expansion, fueled by increasing awareness of family planning, demographic shifts such as delayed parenthood, and the continuous innovation in long-acting reversible contraceptives (LARCs) that offer high efficacy and fewer side effects across diverse patient populations.
Key Takeaways
• The global contraceptive devices market is projected to grow from approximately USD 20.2 billion in 2024 to nearly USD 32.8 billion by 2032, reflecting a…
Trauma Fixation Devices Market Set for Steady Growth at 6.01% CAGR Through 2032: …
The global trauma fixation devices market is poised for strong, sustained expansion, driven by rising incidence of road accidents and trauma cases, growing volumes of orthopedic surgeries, and rapid adoption of advanced fixation technologies including bioabsorbable implants, minimally invasive systems, and AI-assisted surgical tools across key geographies.
Key Takeaways
• The global trauma fixation devices market is projected to grow from USD 8,073.28 million in 2024 to USD 12,795.77 million by 2032,…
More Releases for Psoriatic
Psoriatic Arthritis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Psoriatic Arthritis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Psoriatic Arthritis Research. Learn more about…
Psoriatic Arthritis Treatment: A New Era of Relief
The Business Research Company recently released a comprehensive report on the Global Psoriatic Arthritis Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The psoriatic arthritis treatment…
Psoriatic Arthritis Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Psoriatic Arthritis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Psoriatic Arthritis Pipeline Report
• Over 20+…
Psoriatic Arthritis Treatment Market - Unleash the Power of Relief: Elevating Tr …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Psoriatic Arthritis Treatment Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Psoriatic Arthritis Treatment provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes…
Psoriatic Arthritis Treatment Market Size, CAGR | Growth - 2030
Exclusive Report by Ameco Research: Psoriatic Arthritis Treatment Market Size Projected to Reach USD 26 Billion by 2030, Growing at 9.60% CAGR
Ameco Research is proud to announce the launch of its latest market research report, Psoriatic Arthritis Treatment Market. This comprehensive report provides in-depth analysis and insights into the current market trends and future projections in the Industry/Market Segment. Ameco Research has been at the forefront of providing quality…
Psoriatic Arthritis Treatment Market Growth Framework 2025
Global Psoriatic Arthritis Treatment Market: Overview
The demand within the global psoriatic arthritis treatment market has been rising on account of advancements in the field of healthcare and biosimilar analysis. The occurrence of psoriatic arthritis can place an extremely negative toll on the overall health of individuals. This is because psoriatic arthritis is more severe than any other form of arthritis. Under psoriatic arthritis, patients suffering from a skin condition called…
